We are thrilled to announce the annual meeting for the pivotal phase III trial , priMe, set to take place in Entebbe, Uganda on November 29-30, 2023.
This collaborative effort signifies a crucial moment in advancing the novel tuberculosis vaccine VPM1002 and infant healthcare.
Together, we are set to exchange invaluable experiences, celebrate milestones, and strengthen partnerships. We are excited for insightful discussions, progress assessments, and the recognition of exceptional performances by our trial sites.
Follow updates from the priMe trial consortium (https://www.prime-vaccine.eu/) as they continue to pioneer vaccine development in infant health research and shape a brighter, healthier future for newborns worldwide.